FDA (Drugs) recall action 99399
The FDA (Drugs) publishes a recall like this one as 12 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 12 pages.
Subpotent Drug
The agency’s own wording, quoted from the enforcement report.
Major Pharmaceuticals is voluntarily recalling certain lots of Levothyroxine Sodium Tablets (75 mcg) because the medication may be subpotent.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets (50 mcg) from lot N02200 due to subpotency, meaning the tablets may contain less active ingredient than labeled. Products were distributed nationwide in the USA.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 150 mcg, lot N02167, due to subpotent drug concerns. The recall affects nationwide distribution in the USA.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 50 mcg, due to subpotency. The recall affects nationwide distribution in the USA and involves specific lot numbers.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets (125 mcg) because the medication may be subpotent.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 25 mcg, due to subpotency. The recall affects nationwide U.S. distribution of specific lot numbers.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 88 mcg, lot N02310, due to subpotency. The recall is voluntary and affects nationwide distribution in the USA.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium Tablets, 75 mcg, NDC 0904-6951-61, due to subpotency. The recall affects lots N02172, N02296, and N02288 with expiration dates in July and December 2026, distributed nationwide.
Major Pharmaceuticals is recalling LEVOTHYROXINE SODIUM 150 mcg tablets because some batches contain less active ingredient than labeled, potentially reducing thyroid hormone effectiveness.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 25 mcg, lot N02212, due to subpotency. The recall is nationwide and voluntary.
Major Pharmaceuticals is voluntarily recalling Levothyroxine Sodium 125 mcg tablets (Lot N02266, Exp. 11/2026) nationwide due to subpotency, meaning the tablets may contain less active ingredient than labeled.
Major Pharmaceuticals is recalling Levothyroxine Sodium Tablets, 112 mcg, lot N02203, due to subpotent drug concerns. The recall affects nationwide U.S. distribution and was initiated voluntarily by the firm.